ClinicalTrials.gg
CompletedNCT06258174Updated Jan 13, 2025Results posted

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

A Phase 1 interventional study of Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Sep 2021, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of non-.
  • Within (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m²).
  • Participants will be in good general health, based on medical history, physical examination findings, vital signs, 12 lead (ECG), or clinical laboratory tests, as determined by the Investigator (or designee).

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:

    1. liver disease
    2. pancreatitis
    3. peptic ulcer disease
    4. intestinal malabsorption
    5. cholecystectomy
    6. gastric reduction surgery
    7. history or presence of clinically significant cardiovascular disease.
  • Participants with out-of-range, at-rest vital signs.
  • Abnormal laboratory values determined to be clinically significant by the Investigator (or designee).
  • Clinically significant abnormality, as determined by the Investigator (or designee), from physical examination.
  • Participation in any other study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to Day 1.
  • Use or intention to use any prescription or over-the-counter medications within 14 days prior to Day 1 and through end of trial.
  • History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.
  • Donation of blood from 56 days prior to Screening, plasma or from 4 weeks prior to Screening.
  • Receipt of blood products within 2 months prior to Check-in (Day -1).
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal (GI), neurological, or psychiatric disorder (as determined by the Investigator), or cancer within the past 5 years (except localized basal cell, squamous, or in situ cancer of the skin).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    200 mg Pirtobrutinib (Sequence R/T)

    Period 1: Participants received a reference formulation (R) of oral pirtobrutinib 200 milligrams (mg) on day 1. Period 2: Participants received a test formulation (T) of oral pirtobrutinib 200 mg on day 8. There was a washout period of 7 days between the doses of pirtobrutinib.

    Drug: Pirtobrutinib

  • Experimental
    200 mg Pirtobrutinib (Sequence T/R)

    Period 1: Participants received a test formulation (T) of oral pirtobrutinib 200 mg on day 1. Period 2: Participants received a reference formulation (R) of oral pirtobrutinib 200 mg on day 8. There was a washout period of 7 days between the doses of pirtobrutinib.

    Drug: Pirtobrutinib

Interventions

  • Administered orally.

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

    PK: AUC0-24 of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

    PK: AUC0-inf of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  4. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

    PK: %AUCextrap of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  5. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

    PK: CL/F of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  6. PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

    PK: t1/2 of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  7. PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  8. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  9. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib

    PK: λZ of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  10. PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib

    PK: Vz/F of Pirtobrutinib

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

07

Results

Posted Jan 13, 2025

Participant flow

Participants were randomized to 2 treatment sequences (R/T, T/R), with each sequence having 2 periods where participants were crossed over between the periods. A washout period of 7 days was maintained between doses of each treatment period.

Period 1
Participant flow — Period 1
Milestone200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)
Started1414
Received at least 1 dose of study drug1414
Completed1414
Not completed00
Period 2
Participant flow — Period 2
Milestone200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)
Started1414
Received at least 1 dose of study drug1414
Completed1414
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

PK: AUC0-24 of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib48800 ± 29.149700 ± 20.6
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib81100 ± 3683600 ± 24.7
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

PK: AUC0-inf of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib82000 ± 35.584700 ± 24.4
PrimaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

PK: %AUCextrap of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · percentage of AUCextrap
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
percentage of AUCextrap200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib1.01 ± 46.91.12 ± 36.7
PrimaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

PK: CL/F of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
liter per hour (L/h)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib2.44 ± 35.52.36 ± 24.4
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

PK: t1/2 of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib
hours200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib18.9 ± 21.219 ± 20.3
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

PK: Cmax of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib
nanogram per milliliter (ng/mL)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib3960 ± 23.33980 ± 24.2
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hours200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib2.50 (0.500 to 6)2.50 (0.750 to 6)
PrimaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib

PK: λZ of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib
1/hour (1/h)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
Subject 10.04870.0347
Subject 20.04200.0374
Subject 30.05490.0563
Subject 40.04460.0386
Subject 50.04060.0382
Subject 60.03820.0389
Subject 70.03550.0348
Subject 80.03350.0341
Subject 90.04140.0390
Subject 100.04310.0437
Subject 110.03580.0321
Subject 120.04320.0427
Subject 130.03240.0382
Subject 140.01980.0179
Subject 150.04090.0371
Subject 160.04570.0451
Subject 170.02790.0284
Subject 180.03050.0299
Subject 190.04070.0478
Subject 200.02900.0350
Subject 210.02930.0342
Subject 220.04080.0403
Subject 230.03400.0322
Subject 240.02690.0299
Subject 250.03720.0379
Subject 260.03590.0396
Subject 270.03700.0369
Subject 280.03600.0368
PrimaryPK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib

PK: Vz/F of Pirtobrutinib

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib
Liter (L)200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib66.6 ± 36.764.9 ± 28.4

Adverse events

Collected over Baseline to Follow-up (Up To Day 24). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Pirtobrutinib (Reference Formulation)0/28 (0%)0/28 (0%)0/28 (0%)
200 mg Pirtobrutinib (Test Formulation)0/28 (0%)0/28 (0%)1/28 (3.6%)
Most frequent other events
Most frequent other events
Event200 mg Pirtobrutinib (Reference Formulation)200 mg Pirtobrutinib (Test Formulation)
Dermatitis contactSkin and subcutaneous tissue disorders0/281/28

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)Total
Mean40.2 ± 6.86033.5 ± 9.94036.9 ± 9.050
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)Total
Female213
Male121325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)Total
Hispanic or Latino325
Not Hispanic or Latino111223
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)Total
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American538
White6814
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)200 mg Pirtobrutinib (Sequence R/T)200 mg Pirtobrutinib (Sequence T/R)Total
United States141428
08

Study locations

1 site
  • Labcorp Drug Development
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2021, 2 months.

Results were first posted in Jan 2025, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Sep 28, 2021
Primary completionActual
Dec 22, 2021
CompletionActual
Dec 22, 2021
Results first posted
Jan 13, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06258174
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Sep 28, 2021
Primary completion
Dec 22, 2021
Completion
Dec 22, 2021
Results posted
Jan 13, 2025
Last update
Jan 13, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion